Spyre Therapeutics (SYRE) Receivables (2015 - 2024)
Spyre Therapeutics posted quarterly Receivables of $5.9 million for Q4 2024, little changed on a QoQ basis from $5.9 million in Q3 2024.
Spyre Therapeutics (SYRE) has 5 years of Receivables data on file, last reported at $5.9 million in Q4 2024.
- For the quarter ending Q4 2024, Receivables changed N/A year-over-year to $5.9 million; the trailing twelve-month figure through Dec 2024 stood at $5.9 million (changed N/A YoY), and the FY2024 full-year result was $5.9 million, changed N/A from the prior year.
- Receivables for Q4 2024 stood at $5.9 million, roughly flat from $5.9 million in the prior quarter.
- Across five years, Receivables topped out at $21.5 million in Q1 2021 and bottomed at $5.9 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.90 Mn |
| Sep 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Mar 31, 2021 | 21.50 Mn |
| Sep 30, 2018 | 4.82 Mn |
| Jun 30, 2016 | 3.23 Mn |
| Mar 31, 2016 | 3.22 Mn |
| Dec 31, 2015 | 3.40 Mn |